Abstract

 CADTH recommends that Vraylar should not be reimbursed by public drug plans for the treatment of schizophrenia in adults.
 Based on evidence from 5 clinical trials, treatment with Vraylar improved symptoms of schizophrenia or delayed relapse compared with placebo. Vraylar also improved negative symptoms of schizophrenia compared with risperidone. Although these results were statistically significant, it is not clear whether any of these effects are clinically important.
 It is not clear whether cariprazine offers any clinical benefits over other treatments that are available for schizophrenia because there were no clinical trials in patients with acute schizophrenia that compared Vraylar with any other treatments. The committee did not have confidence in the results because the indirect comparative evidence reviewed had too many limitations.
 There was not enough evidence to show that Vraylar filled a treatment gap.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
